The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Open accessAbstract
Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that work synergistically to promote lesion development. The ability to develop preventive and ameliorative treatments will depend on animal models that mimic the human subject metabolically and pathophysiologically and will develop lesions comparable to those in humans. The mouse is the most useful, economic, and valid model for studying atherosclerosis and exploring effective therapeutic approaches. Among the most widely used mouse models for atherosclerosis are apolipoprotein E–deficient (ApoE −/− ) and LDL receptor–deficient (LDLr −/− ) mice. An up-and-coming model is the ApoE*3Leiden (E3L) transgenic mouse. Here, we review studies that have explored how and to what extent these mice respond to compounds directed at treatment of the risk factors hypercholesterolemia, hypertriglyceridemia, hypertension, and inflammation. An important outcome of this survey is that the different models used may differ markedly from one another in their response to a specific experimental manipulation. The choice of a model is therefore of critical importance and should take into account the risk factor to be studied and the working spectrum of the compounds tested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The immune response in atherosclerosis: a double-edged sword
Hansson, G. K., & Libby, P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1882 · Cited by 2,182
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.133 · Cited by 1,693
Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E–deficient mice
Daugherty, A., Manning, M. W., & Cassis, L. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7818 · Cited by 1,368
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112059299 · Cited by 947
Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., & Glass, C. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10370 · Cited by 833
Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ
Lee, C.-H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W. A., & Evans, R. M. (2003) · Science · doi:10.1126/science.1087344 · Cited by 580
Li, A. C., Binder, C. J., Gutierrez, A., Brown, K. K., Plotkin, C. R., Pattison, J. W., Valledor, A. F., Davis, R. A., Willson, T. M., Witztum, J. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18730 · Cited by 573
Mouse Models of Atherosclerosis
Breslow, J. L. (1996) · Science · doi:10.1126/science.272.5262.685 · Cited by 549
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
Ferrario, C. M., & Strawn, W. B. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.059 · Cited by 512
Atherosclerosis in the Apolipoprotein E–Deficient Mouse: A Decade of Progress
Meir, K. S., & Leitersdorf, E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000128849.12617.f4 · Cited by 498
p47phox is required for atherosclerotic lesion progression in ApoE–/– mice
Barry-Lane, P. A., Patterson, C., van der Merwe, M., Hu, Z., Holland, S. M., Yeh, E. T. H., & Runge, M. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200111927 · Cited by 489
Identification of macrophage liver X receptors as inhibitors of atherosclerosis
Tangirala, R. K., Bischoff, E. D., Joseph, S. B., Wagner, B. L., Walczak, R., Laffitte, B. A., Daige, C. L., Thomas, D., Heyman, R. A., Mangelsdorf, D. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182199799 · Cited by 438
Sparrow, C. P., Burton, C. A., Hernandez, M., Mundt, S., Hassing, H., Patel, S., Rosa, R., Hermanowski-Vosatka, A., Wang, P.-R., Zhang, D., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.1.115 · Cited by 413
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S., Wakino, S., Noh, G., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 385
Weiss, D., Kools, J. J., & Taylor, W. R. (2001) · Circulation · doi:10.1161/01.cir.103.3.448 · Cited by 368
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
Li, A. C., & Glass, C. K. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400010-jlr200 · Cited by 357
Terasaka, N., Hiroshima, A., Koieyama, T., Ubukata, N., Morikawa, Y., Nakai, D., & Inaba, T. (2003) · FEBS Letters · doi:10.1016/s0014-5793(02)03578-0 · Cited by 326
Apo E structure determines VLDL clearance and atherosclerosis risk in mice
Knouff, C., Hinsdale, M. E., Mezdour, H., Altenburg, M. K., Watanabe, M., Quarfordt, S. H., Sullivan, P. M., & Maeda, N. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6172 · Cited by 324
Diet and Murine Atherosclerosis
Getz, G. S., & Reardon, C. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201071.49029.17 · Cited by 324
Chen, Z., Ishibashi, S., Perrey, S., Osuga, J.-I., Gotoda, T., Kitamine, T., Tamura, Y., Okazaki, H., Yahagi, N., Iizuka, Y., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.372 · Cited by 320
Knowles, J. W., Reddick, R. L., Jennette, J. C., Shesely, E. G., Smithies, O., & Maeda, N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8376 · Cited by 305
Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J.-C., Laudet, V., & Staels, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25713 · Cited by 297
Claudel, T., Leibowitz, M. D., Fiévet, C., Tailleux, A., Wagner, B., Repa, J. J., Torpier, G., Lobaccaro, J.-M., Paterniti, J. R., Mangelsdorf, D. J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041609298 · Cited by 292
Macrophage Liver X Receptor Is Required for Antiatherogenic Activity of LXR Agonists
Levin, N., Bischoff, E. D., Daige, C. L., Thomas, D., Vu, C. T., Heyman, R. A., Tangirala, R. K., & Schulman, I. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000150044.84012.68 · Cited by 284
Sullivan, P. M., Mezdour, H., Quarfordt, S. H., & Maeda, N. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2673 · Cited by 264
Candido, R., Jandeleit-Dahm, K. A., Cao, Z., Nesteroff, S. P., Burns, W. C., Twigg, S. M., Dilley, R. J., Cooper, M. E., & Allen, T. J. (2002) · Circulation · doi:10.1161/01.cir.0000021122.63813.32 · Cited by 261
Daugherty, A., Rateri, D. L., Lu, H., Inagami, T., & Cassis, L. A. (2004) · Circulation · doi:10.1161/01.cir.0000150540.54220.c4 · Cited by 258
Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
van Vlijmen, B. J., van den Maagdenberg, A. M., Gijbels, M. J., van der Boom, H., HogenEsch, H., Frants, R. R., Hofker, M. H., & Havekes, L. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117117 · Cited by 250
Shiri-Sverdlov, R., Wouters, K., Gorp, P. J. V., Gijbels, M. J., Noel, B., Buffat, L., Staels, B., Maeda, N., Bilsen, M. V., & Hofker, M. H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.033 · Cited by 241
Johnson, J., Carson, K., Williams, H., Karanam, S., Newby, A., Angelini, G., George, S., & Jackson, C. (2005) · Circulation · doi:10.1161/01.cir.0000158435.98035.8d · Cited by 241
Westerterp, M., van der Hoogt, C. C., de Haan, W., Offerman, E. H., Dallinga-Thie, G. M., Jukema, J. W., Havekes, L. M., & Rensen, P. C. N. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000243925.65265.3c · Cited by 233
PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
Tordjman, K., Bernal-Mizrachi, C., Zemany, L., Weng, S., Feng, C., Zhang, F., Leone, T. C., Coleman, T., Kelly, D. P., & Semenkovich, C. F. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11497 · Cited by 229
Scalia, R., Gooszen, M. E., Jones, S. P., Hoffmeyer, M., Rimmer, D. M., Trocha, S. D., Huang, P. L., Smith, M. B., Lefer, A. M., & Lefer, D. J. (2001) · Circulation · doi:10.1161/01.cir.103.21.2598 · Cited by 204
Ballantyne, C. M., Blazing, M. A., King, T. R., Brady, W. E., & Palmisano, J. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.060 · Cited by 202
The PPARδ agonist GW0742X reduces atherosclerosis in LDLR−/− mice
Graham, T. L., Mookherjee, C., Suckling, K. E., A. Palmer, C. N., & Patel, L. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.028 · Cited by 201
Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis
Candido, R., Allen, T. J., Lassila, M., Cao, Z., Thallas, V., Cooper, M. E., & Jandeleit-Dahm, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000124061.78478.94 · Cited by 195
Powell-Braxton, L., Véniant, M., Latvala, R. D., Hirano, K.-I., Won, W. B., Ross, J., Dybdal, N., Zlot, C. H., Young, S. G., & Davidson, N. O. (1998) · Nature Medicine · doi:10.1038/nm0898-934 · Cited by 192
Duez, H., Chao, Y.-S., Hernandez, M., Torpier, G., Poulain, P., Mundt, S., Mallat, Z., Teissier, E., Burton, C. A., Tedgui, A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206966200 · Cited by 186
Grainger, D. J., Reckless, J., & McKilligin, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6366 · Cited by 183
Davis, H. R., Compton, D. S., Hoos, L., & Tetzloff, G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1201.100260 · Cited by 182
Willner, E. L., Tow, B., Buhman, K. K., Wilson, M., Sanan, D. A., Rudel, L. L., & Farese, R. V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336398100 · Cited by 181
Kleemann, R., Verschuren, L., de Rooij, B.-J., Lindeman, J., de Maat, M. M., Szalai, A. J., Princen, H. M. G., & Kooistra, T. (2004) · Blood · doi:10.1182/blood-2003-11-3791 · Cited by 180
Self-citationApolipoprotein E Suppresses the Type I Inflammatory Response In Vivo
Ali, K., Middleton, M., Puré, E., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000187467.67684.43 · Cited by 179
Wassmann, S., Czech, T., van Eickels, M., Fleming, I., Böhm, M., & Nickenig, G. (2004) · Circulation · doi:10.1161/01.cir.0000137970.47771.af · Cited by 177
Resistin: molecular history and prognosis
Banerjee, R. R., & Lazar, M. A. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0428-9 · Cited by 172
Genetic Modifiers of Atherosclerosis in Mice
Knowles, J. W., & Maeda, N. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.11.2336 · Cited by 171
Sanan, D. A., Newland, D., Tao, R., Marcovina, S. M., Wang, J., Mooser, V., Hammer, R. E., & Hobbs, H. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4544 · Cited by 167
Lund, E. G., Peterson, L. B., Adams, A. D., Lam, M.-H. N., Burton, C. A., Chin, J., Guo, Q., Huang, S., Latham, M., Lopez, J. C., et al. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.11.004 · Cited by 165
Kleemann, R., Princen, H. M. G., Emeis, J. J., Jukema, J. W., Fontijn, R. D., Horrevoets, A. J. G., Kooistra, T., & Havekes, L. M. (2003) · Circulation · doi:10.1161/01.cir.0000086460.55494.af · Cited by 165
Self-citationHayek, T., Attias, J., Coleman, R., Brodsky, S., Smith, J., Breslow, J. L., & Keidar, S. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00239-4 · Cited by 161
Kwak, B. R., Veillard, N. R., Pelli, G., Mulhaupt, F., James, R. W., Chanson, M., & Mach, F. (2003) · Circulation · doi:10.1161/01.cir.0000051364.70064.d1 · Cited by 157
Bea, F., Blessing, E., Bennett, B. J., Levitz, M., Wallace, E. P., & Rosenfeld, M. E. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000036081.01231.16 · Cited by 153
Navab, M., Anantharamaiah, G. M., Hama, S. Y., Hough, G., Reddy, S. T., Frank, J. S., Garber, D. W., Handattu, S. P., & Fogelman, A. M. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000167412.98221.1a · Cited by 146
Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation
da Cunha, V., Tham, D. M., Martin-McNulty, B., Deng, G. G., Ho, J. J., Wilson, D. W., Rutledge, J. C., Vergona, R. A., Sullivan, M. E., & Wang, Y. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.023 · Cited by 145
Keidar, S., Attias, J., Smith, J. D., Breslow, J. L., & Hayek, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6844 · Cited by 141
Mazzolai, L., Duchosal, M. A., Korber, M., Bouzourène, K., Aubert, J. F., Hao, H., Vallet, V., Brunner, H. R., Nussberger, J., Gabbiani, G., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000140269.55873.7b · Cited by 139
Apolipoprotein E modulates immune activation by acting on the antigen‐presenting cell
Tenger, C., & Zhou, X. (2003) · Immunology · doi:10.1046/j.1365-2567.2003.01665.x · Cited by 129
Toll-Like Receptors, Endocrine Stress Response, and Arteriosclerosis
Bornstein, S. R., & Morawietz, H. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000178996.91277.fb · Cited by 128
Calkin, A. C., Forbes, J. M., Smith, C. M., Lassila, M., Cooper, M. E., Jandeleit-Dahm, K. A. M., & Allen, T. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000177813.99577.6b · Cited by 126
Pathophysiological regulation of the AT1-receptor and implications for vascular disease
Waßmann, S., & Nickenig, G. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220402.53869.72 · Cited by 124
Suzuki, J., Iwai, M., Mogi, M., Oshita, A., Yoshii, T., Higaki, J., & Horiuchi, M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000204635.75748.0f · Cited by 123
Deficiency of Niemann-Pick C1 Like 1 Prevents Atherosclerosis in ApoE−/−Mice
Davis, H. R., Hoos, L. M., Tetzloff, G. G., Maguire, M., Zhu, L.-J., Graziano, M. P., & Altmann, S. W. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000257627.40486.46 · Cited by 122
Apolipoprotein E and Atherosclerosis: Beyond Lipid Effect
Davignon, J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000154570.50696.2c · Cited by 121
Herrera, V. L. M., Makrides, S. C., Xie, H. X., Adari, H. Y., Krauss, R. M., Ryan, U. S., & Ruiz‐Opazo, N. (1999) · Nature Medicine · doi:10.1038/70956 · Cited by 120
Delsing, D. J. M., Offerman, E. H., van Duyvenvoorde, W., van der Boom, H., de Wit, E. C. M., Gijbels, M. J., van der Laarse, A., Jukema, J. W., Havekes, L. M., & Princen, H. M. G. (2001) · Circulation · doi:10.1161/01.cir.103.13.1778 · Cited by 116
Self-citationAtherosclerosis in APOE*3-Leiden Transgenic Mice: From Proliferative to Atheromatous Stage
Lutgens, E., Daemen, M. J. A. P., Kockx, M. M., Doevendans, P. A., Hofker, M. H., Havekes, L. M., Wellens, H. J. J., & de Muinck, E. D. (1999) · Circulation · doi:10.1161/01.cir.99.2.276 · Cited by 115
Ni, W., Kitamoto, S., Ishibashi, M., Usui, M., Inoue, S., Hiasa, K., Zhao, Q. D., Nishida, K.-I., Takeshita, A., & Egashira, K. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000118275.60121.2b · Cited by 113
Takaya, T., Kawashima, S., Shinohara, M., Yamashita, T., Toh, R., Sasaki, N., Inoue, N., Hirata, K., & Yokoyama, M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.009 · Cited by 112
Tsuda, M., Iwai, M., Li, J., Li, H.-S., Min, L., Ide, A., Okumura, M., Suzuki, J., Mogi, M., Suzuki, H., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000157409.88971.fc · Cited by 111
Antiatherosclerotic and Antioxidative Effects of Captopril in Apolipoprotein E-Deficient Mice
Hayek, T., Attias, J., Smith, J. D., Breslow, J. L., & Keidar, S. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199804000-00011 · Cited by 108
Kusunoki, J., Hansoty, D. K., Aragane, K., Fallon, J. T., Badimón, J. J., & Fisher, E. A. A. (2001) · Circulation · doi:10.1161/01.cir.103.21.2604 · Cited by 104
Keidar, S., Attias, J., Heinrich, R., Coleman, R., & Aviram, M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00145-8 · Cited by 104
Bea, F., Blessing, E., Shelley, M. I., Shultz, J. M., & Rosenfeld, M. E. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00387-8 · Cited by 100
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Srivastava, R. A. K., Jahagirdar, R., Azhar, S., Sharma, S., & Bisgaier, C. L. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-9053-y · Cited by 95
Raffaï, R. L., Loeb, S. M., & Weisgraber, K. H. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000152613.83243.12 · Cited by 94
Dol, F., Martin, G., Staels, B., Marés, A.-M., Cazaubon, C., Nisato, D., Bidouard, J., Janiak, P., Schaeffer, P., & Herbert, J. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200109000-00008 · Cited by 93
Liver X receptors in cardiovascular and metabolic disease
Geyeregger, R., Zeyda, M., & Stulnig, T. M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5398-3 · Cited by 91
Sjöland, H., Eitzman, D. T., Gordon, D., Westrick, R. J., Nabel, E. G., & Ginsburg, D. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.3.846 · Cited by 87
Li, A. C., & Palinski, W. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141247 · Cited by 86
Chen, Z., Fukutomi, T., Zago, A. C., Ehlers, R., Detmers, P. A., Wright, S. D., Rogers, C., & Simon, D. I. (2002) · Circulation · doi:10.1161/01.cir.0000022843.76104.01 · Cited by 85
Sata, M., Nishimatsu, H., Osuga, J.-I., Tanaka, K., Ishizaka, N., Ishibashi, S., Hirata, Y., & Nagai, R. (2004) · Hypertension · doi:10.1161/01.hyp.0000126186.29571.41 · Cited by 83
Peripheral vascular disease and hypertension: a forgotten association?
Makin, A., Lip, G. Y. H., Silverman, S., & Beevers, D. G. (2001) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001209 · Cited by 81
Verschuren, L., Kleemann, R., Offerman, E. H., Szalai, A. J., Emeis, S. J., Princen, H. M. G., & Kooistra, T. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000148866.29829.19 · Cited by 81
Self-citationLi, Z., Iwai, M., Wu, L., Liu, H., Chen, R., Jinno, T., Suzuki, J., Tsuda, M., Gao, X.-Y., Okumura, M., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000145179.44166.0f · Cited by 81
Kooistra, T., Verschuren, L., der Weij, J. D. V.-V., Köenig, W., Toet, K. H., Princen, H. M. G., & Kleemann, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000238348.05028.14 · Cited by 80
Self-citationHennuyer, N., Tailleux, A., Torpier, G., Mezdour, H., Fruchart, J., Staels, B., & Fiévet, C. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000175756.56818.ee · Cited by 80
Calkin, A. C., Cooper, M. E., Jandeleit-Dahm, K. A. M., & Allen, T. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0102-6 · Cited by 80
Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E
Wang, Y.-X., Martin-McNulty, B., Huw, L., da Cunha, V., Post, J., Hinchman, J., Vergona, R. A., Sullivan, M. E., Dole, W. P., & Kauser, K. Z. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00678-5 · Cited by 79
PPARs and LXRs: atherosclerosis goes nuclear
Barish, G. D., & Evans, R. M. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.03.003 · Cited by 77
van de Poll, S. W. E., Römer, T. J., Volger, O. L., Delsing, D. J. M., Schut, T. C. B., Princen, H. M. G., Havekes, L. M., Jukema, J. W., van der Laarse, A., & Puppels, G. J. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1001.096651 · Cited by 73
Self-citationBisgaier, C. L., Essenburg, A. D., Auerbach, B. J., Pape, M. E., Sekerke, C., Gee, A., Wolle, S., & Newton, R. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30035-3 · Cited by 72
Levi, Z., Shaish, A., Yacov, N., Levkovitz, H., Trestman, S., Gerber, Y., Cohen, H. W., Dvir, A., Rhachmani, R., Ravid, M., et al. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00240.x · Cited by 71
Grass, D., Saini, U., Felkner, R. H., Wallace, R., Lago, W., Young, S. G., & Swanson, M. E. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39866-7 · Cited by 67
Wu, J. T., & Wu, L. (2005) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.10.016 · Cited by 66
Phosphorylation of NF-KB1-p50 is involved in NF-kappa B activation and stable DNA binding.
Li, C. C., Dai, R. M., Chen, E., & Longo, D. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43777-5 · Cited by 65
Keidar, S., Attias, J., Coleman, R., WIRTH, K. J., Schölkens, B. A., & Hayek, T. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200001000-00008 · Cited by 62
de Nigris, F., D’Armiento, F. P., Somma, P., Casini, A., Andreini, I., Sarlo, F., Mansueto, G., Rosa, G. D., Bonaduce, D., Condorelli, M., et al. (2001) · International Journal of Cardiology · doi:10.1016/s0167-5273(01)00542-3 · Cited by 62
Peroxisome Proliferator-Activated Receptors and Liver X Receptors in Atherosclerosis and Immunity
Barish, G. D. (2006) · Journal of Nutrition · doi:10.1093/jn/136.3.690 · Cited by 57
Grothusen, C., Bley, S., Selle, T., Luchtefeld, M., Grote, K., Tietge, U. J. F., Drexler, H., & Schieffer, B. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.01.045 · Cited by 57
Delsing, D. J. M., Jukema, J. W., van de Wiel, M. A., EMEIS, J. J., van der Laarse, A., Havekes, L. M., & Princen, H. M. G. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200307000-00010 · Cited by 48
Self-citationFu, T., Kashireddy, P. V., & Borensztajn, J. (2003) · Biochemical Journal · doi:10.1042/bj20030105 · Cited by 48
Suzuki, J., Iwai, M., Li, Z., Li, J., Min, L., Ide, A., Yoshii, T., Oshita, A., Mogi, M., & Horiuchi, M. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000173521.91104.5f · Cited by 47
Zadelaar, A. S. M., Boesten, L. S. M., Jukema, J. W., van Vlijmen, B. J. M., Kooistra, T., EMEIS, J. J., Lundholm, E., Camejo, G., & Havekes, L. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000242904.34700.66 · Cited by 47
Self-citationRaal, F. J., Marais, A. D., Klepack, E., Lovalvo, J. L., McLain, R. W., & Heinonen, T. M. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.07.011 · Cited by 46
Hayek, T., Kaplan, M., Raz, A., Keidar, S., Coleman, R., & Aviram, M. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00621-9 · Cited by 45
Doran, D. E., Weiss, D., Zhang, Y., Griendling, K. K., & Taylor, W. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.030 · Cited by 44
Ferrario, C. M., Smith, R. D., Levy, P. J., & Strawn, W. B. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200201000-00004 · Cited by 43
Chira, E. C., McMillen, T. S., Wang, S., Haw, A., O’Brien, K. D., Wight, T. N., & Chait, A. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.012 · Cited by 37
Bocan, T. M. A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00713-9 · Cited by 36
van de Poll, S. W. E., Delsing, D. J. M., Jukema, J. W., Princen, H. M. G., Havekes, L. M., Puppels, G. J., & van der Laarse, A. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00055-2 · Cited by 36
Self-citationFluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice
Gervais, M., Pons, S., Nicoletti, A., Cosson, C., Giudicelli, J., & Richer, C. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000051404.84665.49 · Cited by 35
In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice.
Sh, Q., Oswald, B. S., Landis, B. A., Xu, H., Zhang, S. H., & Maeda, N. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41130-7 · Cited by 35
Game, B. A., He, L., Jarido, V., Nareika, A., Jaffa, A. A., Lopes-Virella, M. F., & Huang, Y. Q. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.06.025 · Cited by 34
Zuckerman, S. H., Kauffman, R. F., & Evans, G. F. (2002) · Lipids · doi:10.1007/s11745-002-0922-2 · Cited by 33
Fu, T., Mukhopadhyay, D., Davidson, N. O., & Borensztajn, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403271200 · Cited by 33
Chiwata, T., Aragane, K., Fujinami, K., Kojima, K., Ishibashi, S., Yamada, N., & Kusunoki, J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704160 · Cited by 32
Antiatherogenic Effects of Angiotensin Receptor Antagonism in Mild Renal Dysfunction
Suganuma, E., Zuo, Y., Ayabe, N., Ma, J., Babaev, V. R., Linton, M. F., Fazio, S., Ichikawa, I., Fogo, A. B., & Kon, V. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080883 · Cited by 32
Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
van Vlijmen, B. J. M., Pearce, N. J., Bergö, M. O., Staels, B., Yates, J. W., Gribble, A. D., Bond, B. C., Hofker, M. H., Havekes, L. M., & Groot, P. H. E. (1998) · PubMed · Cited by 31
Choudhury, R. P., Carrelli, A. L., Stern, J. D., Chereshnev, I., Soccio, R. E., Elmalem, V. I., Fallon, J. T., Fisher, E. A. A., & Reis, E. D. (2004) · Journal of Vascular Research · doi:10.1159/000076436 · Cited by 31
Gaining weight: the Keystone Symposium on PPAR and LXRPreprint
Lehrke, M., Pascual, G., Glass, C. K., & Lazar, M. A. (2005) · Genes & Development · doi:10.1101/gad.1341005 · Cited by 31
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse
Calkin, A. C., Allen, T. J., Lassila, M., Tikellis, C., Jandeleit-Dahm, K. A. M., & Thomas, M. C. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.021 · Cited by 29
Yeganeh, B., Moshtaghi‐Kashanian, G., DeClercq, V., & Moghadasian, M. H. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.12.003 · Cited by 28
Paradoxical Effects of Fenofibrate and Nicotinic Acid in Apo E-Deficient Mice
DeClercq, V., Yeganeh, B., Moshtaghi‐Kashanian, G., Khademi, H., Bahadori, B., & Moghadasian, M. H. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000162764.12309.25 · Cited by 24
Gälman, C., Östlund‐Lindqvist, A., Björquist, A., Schreyer, S. A., Svensson, L., Angelin, B., & Rudling, M. J. (2002) · The FASEB Journal · doi:10.1096/fj.02-0341fje · Cited by 24
Zhou, Y., CHEN, R., Catanzaro, S., Hu, L., Dansky, H. M., & Catanzaro, D. F. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.11.005 · Cited by 23
Delsing, D. J. M., Post, S. M., Groenendijk, M., Solaas, K., van der Boom, H., van Duyvenvoorde, W., de Wit, E. C. M., Bloks, V. W., Kuipers, F., Havekes, L. M., et al. (2004) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200501000-00010 · Cited by 22
Self-citationNachtigal, P., Pospisilova, N., Pospěchová, K., Jamborova, G., Kopecký, M., Jaynes, R., Briestenský, J., Santar, I., Šmahelová, A., Solichová, D., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.08.041 · Cited by 20
Analysis of gender-specific atherosclerosis susceptibility in transgenic[hCETP]25DS rat model
Herrera, V. L. M., Tsikoudakis, A., Didishvili, T., et al. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.017 · Cited by 19
He, L., Game, B. A., Nareika, A., Garvey, W. T., & Huang, Y. Q. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000248831.21973.c4 · Cited by 16
Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport?
Rensen, P., & Havekes, L. (2006) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000214979.24518.95 · Cited by 15
Simvastatin causes the formation of cholesterol-rich remnants in mice lacking apoE
Fu, T., & Borensztajn, J. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.071 · Cited by 14
Sharabi, Y., Grossman, E., Sherer, Y., Shaish, A., Levkovitz, H., Bitzur, R., & Harats, D. (2000) · Pathobiology · doi:10.1159/000055937 · Cited by 5
Cited by
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Cytokines and atherosclerosis: a comprehensive review of studies in mice
Kleemann, R., Zadelaar, S., & Kooistra, T. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn120 · Cited by 606
Self-citationPathological effects of ionizing radiation: endothelial activation and dysfunction
Baselet, B., Sonveaux, P., Baatout, S., & Aerts, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2956-z · Cited by 552
Animal models of atherosclerosis
Emini Veseli, B., Perrotta, P., De Meyer, G. R. A., Roth, L., Van der Donckt, C., Martinet, W., & De Meyer, G. R. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.010 · Cited by 548
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
Metadata
- Authors
- Zadelaar, S., Kleemann, R., Verschuren, L., de Vries-Van der Weij, J., van der Hoorn, J., Princen, H. M., & Kooistra, T.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2007-08
- Volume
- 27
- Issue
- 8
- Pages
- 1706-1721
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2105924650
- Cited by
- 527
- References
- 139
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.